Skip to main content
Premium Trial:

Request an Annual Quote

Canadian MDx Firm Gets Investment from OGI

NEW YORK (GenomeWeb News) – The Ontario Genomics Institute today said that it has invested an undisclosed amount in Cytognomix, a London, Ontario-based developer of cytogenetic DNA probes for potential use in diagnostics.

The firm is developing single cell DNA probes that are smaller and more densely distributed across chromosomes than probes that are currently commercially available, said OGI. These fluorescent probes can be designed to specifically target and detect chromosomal abnormalities, such as those underlying cancer.

"The investment from OGI will help us in the development of more probes for more genetic diseases, building on the existing 400 probes for around 100 diseases," said Peter Rogan, co-founder of Cytognomix. "Our long-term goal is to manufacture probes that doctors could use to diagnose literally hundreds of disorders on the spot."

OGI's investment was made through its Pre-commercialization Business Development Fund program.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.